Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 40 of 40 results for prostatectomy

  1. Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia (IPG798)

    Evidence-based recommendations on transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia. This involves using laser energy to destroy some of the prostate tissue.

  2. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer (IPG752)

    Evidence-based recommendations on biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. This involves pushing the rectum slightly away from the prostate by inserting a balloon or injecting a gel (spacer) between them.

  3. iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB306)

    NICE has developed a medtech innovation briefing (MIB) on iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia .

  4. Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB315)

    NICE has developed a medtech innovation briefing (MIB) on Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia .

  5. Laparoscopic radical prostatectomy (IPG16)

    This guidance has been updated and replaced by NICE interventional procedure guidance 193.

  6. The Oncentra Prostate v4.x for ultrasound‑guided real‑time HDR brachytherapy in men with localised prostate cancer (MIB16)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Oncentra Prostate v4.x ultrasound-guided real-time HDR brachytherapy in men with localised

  7. Hemosep for cell salvage (MIB103)

    NICE has developed a medtech innovation briefing (MIB) on Hemosep for cell salvage .

  8. MRI fusion biopsy systems for diagnosing prostate cancer (HTG678)

    Evidence-based recommendations on MRI fusion biopsy systems for diagnosing prostate cancer.

  9. Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)

    Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.

  10. Cutting-edge robotic surgery gets green light as 11 systems are recommended

    Eleven cutting-edge robotic surgery systems have been approved for use, potentially transforming care for thousands of NHS patients undergoing soft tissue and orthopaedic procedures.